Zumutor Biologics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$7.3M
- Investors
-
12
Zumutor Biologics General Information
Description
Operator of an immuno-oncology company intended to offer targeted cell therapeutics. The company develops diverse human antibody libraries to identify novel Immunotherapies and improved monoclonal antibodies and targets certain receptors that block NK cell inhibitory signals and allow NK cell activation to generate a potent immune response, enabling clinicians to access novel immunotherapies that target innate immunity and regulate the tumor microenvironment.
Contact Information
Website
www.zumutor.comCorporate Office
- CIC Cambridge Campus
- 1 Broadway
- Cambridge, MA 02142
- United States
Corporate Office
- CIC Cambridge Campus
- 1 Broadway
- Cambridge, MA 02142
- United States
Zumutor Biologics Timeline
Zumutor Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series A) | 13-Jun-2026 | $7.3M | Completed | Clinical Trials - Phase 1 | ||
| 8. Later Stage VC (Series A) | 23-Feb-2026 | Completed | Clinical Trials - Phase 1 | |||
| 7. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 6. Later Stage VC (Series A) | 08-Apr-2025 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series A) | 31-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series A2) | 12-Nov-2019 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC (Series A1) | 30-May-2018 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 01-Jan-2015 | $5.6M | $11.6M | Completed | Startup | |
| 1. Seed Round | 11-Oct-2013 | $6M | $6M | Completed | Startup |
Zumutor Biologics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A5 | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A | 18,924,405 | $0.001000 | 8% | $0.29 | $0.29 | 1x | $0.29 | 9.33% |
| Seed | 24,955,233 | $0.001000 | 8% | $0.18 | $0.18 | 1x | $0.18 | 12.31% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Zumutor Biologics Comparisons
Industry
Financing
Details
Zumutor Biologics Competitors (43)
One of Zumutor Biologics’s 43 competitors is ArsenalBio, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ArsenalBio | Venture Capital-Backed | South San Francisco, CA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Adicet Bio | Formerly VC-backed | Boston, MA |
Zumutor Biologics Patents
Zumutor Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2020202832-A | Non-fucosylated protein and methods | Pending | 10-Jul-2020 | ||
| AU-2020222891-A1 | Anti-clec2d antibodies and methods of use thereof | Active | 11-Feb-2019 | ||
| AU-2020222891-B2 | Anti-clec2d antibodies and methods of use thereof | Active | 11-Feb-2019 | ||
| CA-3129818-A1 | Anti-clec2d antibodies and methods of use thereof | Pending | 11-Feb-2019 | ||
| EP-3924385-A1 | Anti-clec2d antibodies and methods of use thereof | Pending | 11-Feb-2019 | C07K16/2851 |
Zumutor Biologics Signals
Zumutor Biologics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Premji Invest | Growth/Expansion | Minority | ||
| Angel (individual) | Minority | |||
| 3iPartners | Venture Capital | Minority | ||
| Startfresh Ventures | Venture Capital | Minority |
Zumutor Biologics FAQs
-
When was Zumutor Biologics founded?
Zumutor Biologics was founded in 2013.
-
Where is Zumutor Biologics headquartered?
Zumutor Biologics is headquartered in Cambridge, MA.
-
What is the size of Zumutor Biologics?
Zumutor Biologics has 24 total employees.
-
What industry is Zumutor Biologics in?
Zumutor Biologics’s primary industry is Drug Discovery.
-
Is Zumutor Biologics a private or public company?
Zumutor Biologics is a Private company.
-
What is the current valuation of Zumutor Biologics?
The current valuation of Zumutor Biologics is .
-
What is Zumutor Biologics’s current revenue?
The current revenue for Zumutor Biologics is .
-
How much funding has Zumutor Biologics raised over time?
Zumutor Biologics has raised $40.9M.
-
Who are Zumutor Biologics’s investors?
, Premji Invest, , 3iPartners, and Startfresh Ventures are 5 of 12 investors who have invested in Zumutor Biologics.
-
Who are Zumutor Biologics’s competitors?
ArsenalBio, Nkarta Therapeutics, CytomX Therapeutics, Kite Pharma, and Adicet Bio are some of the 43 competitors of Zumutor Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process